Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine

4 abstracts

Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.
Org: Gustave Roussy Cancer Center, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology, Clinical Oncology Department, IRCCS Ospedale Policlinico San Martino Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino Genoa,
Abstract
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
Org: Mayo Clinic, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Department of Hematology and Oncology, Mayo Clinic Florida, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,